Svenska

Inhalation Sciences wins new IRS order worth 100,000 Euro (1.14 MSEK) from prominent European pharma company

Report this content

Inhalation Sciences AB (ISAB) has received a new order worth 100 kEuro (1.14 MSEK) for an Inhalation Research Services (IRS) project from a major European company with a leading pipeline in inhaled therapies, that is a regular client of both ISAB’s products and services. The project will use ISAB’s XposeALI in vitro exposure module.

ISAB’s XposeALI in vitro cell exposure module is connected to the company’s multi-modular aerosol generating platform PreciseInhale. The set-up delivers a precise and even dispersion of test aerosol particles directly onto the cell surface, hence the exposure is called “Air-Liquid Interface”, simulating what occurs on the lung lining when the drug is inhaled.

Reducing test substance costs

The cost of test substances and animal testing is a substantial and growing expense in the development of inhaled therapies. The XposeALI in vitro method significantly reduces the amount of test materials required, as PreciseInhale allows customizable doses of aerosol using minimal amounts of test substance. A full PK study using PreciseInhale can require as little as 100 milligrams of test substance compared to 100g using conventional methods.  

Minimizing animal testing

In vitro testing is growing in importance also in the frame of regulatory guidelines, possibly reducing the future need for animal testing. This not only cuts costs but also aligns with 3R guidelines, a guiding framework on the ethical use of animals recognized by much of the industry and its funding bodies.

Leading the way in in vitro testing

ISAB is increasingly gaining a reputation as a leading innovator and provider of in vitro research services, offering permeability and dissolution studies for inhaled drug development through instruments like XposeALI and its in vitro dissolution testing module DissolvIt.

CEO Manoush Masarrat: “Once again we’re witnessing the growing demand for advanced in vitro testing systems like XposeALI, as the powerful benefits are increasingly understood and recognized. We extend a warm welcome to our returning client”.

Discover ISAB’s in vitro testing modules

  • Read ISAB’s publications on XposeALI here. 
  • Discover XposeALI’s capabilities here.
  • Read ISAB’s publications on DissolvIthere.
  • Discover DissolvIt’s in vitro capabilities here.
  • Explore Inhalation Research Services here.

For more information about Inhalation Sciences, please contact:

Manoush Masarrat, CEO

E-mail: Manoush.masarrat@inhalation.se

Mobile: +46 (0)73 628 9153

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.

The information above was provided by Inhalation Sciences Sweden AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on 21 November 2023.

Taggar:

Inhalation lung research aerosol news aerosol generation lung cell research inhaled drug assessment inhaled drugs

Prenumerera

Dokument & länkar